Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Acquisition
Strides Acquires Identified ANDAs from Nostrum Laboratories, USA
Details : The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.
Product Name : Nitrofurantoin-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 03, 2025
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Strides Pharma Science
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Partnership
CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization
Details : Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.
Product Name : Nitrofurantoin PR-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
December 16, 2024
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Adalvo
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | Boston University | University of Colorado, Denver | University of North Carolina, Chapel Hill | International Centre for Diarrhoeal Disease Research, Bangladesh | K
Deal Size : Inapplicable
Deal Type : Inapplicable
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : University of Alabama at Birmingham | Thomas Jefferson University | Columbia University | Boston University | University of Colorado, Denver | University of North Carolina, Chapel Hill | International Centre for Diarrhoeal Disease Research, Bangladesh | K
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
Details : Nitrofurantoin is activated inside bacteria by reduction via the flavoprotein nitrofurantoin reductase to unstable metabolites, which disrupt ribosomal RNA, DNA and other intracellular components. It is bactericidal, especially to bacteria present in aci...
Product Name : Furadantin-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 24, 2023
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : IBSA Institut Biochimique | Goodlife Pharma B.V.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : IBSA Institut Biochimique | Goodlife Pharma B.V.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nitrofurantoin capsules, USP (Macrocrystals) is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella an...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitrofurantoin,Cranberry
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Theralogix
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 14, 2018
Lead Product(s) : Nitrofurantoin,Cranberry
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Theralogix
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 24, 2010
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable